Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glycerin SCHEMBL3685666 | 1.00 | LMNA (0.53) | LMNAALDH1A1THRBTDP1TSHR | |
| Glycerin SCHEMBL19453124 | 0.97 | LMNA (0.50) | LMNAALDH1A1THRBTDP1 | |
| Glycerin SCHEMBL4330923 | 0.94 | LMNA (0.60) | LMNAALDH1A1THRBTDP1TSHR | |
| Glycerin SCHEMBL343633 | 0.94 | — | — | |
| Glycerin SCHEMBL9770227 | 0.94 | LMNA (0.60) | LMNAALDH1A1THRBTDP1TSHR | |
| Glycerin SCHEMBL13279055 | 0.94 | LMNA (0.60) | LMNAALDH1A1THRBTDP1TSHR | |
| Glycerin SCHEMBL9770368 | 0.94 | LMNA (0.60) | LMNAALDH1A1THRBTDP1TSHR | |
| Glycerin SCHEMBL10475823 | 0.94 | LMNA (0.60) | LMNAALDH1A1THRBTDP1TSHR | |
| Glycerin SCHEMBL2674761 | 0.94 | LMNA (0.60) | LMNAALDH1A1THRBTDP1TSHR | |
| Glycerin SCHEMBL29283590 | 0.91 | LMNA (0.56) | LMNAALDH1A1THRBTDP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106414626-B | Ink composition | 惠普发展公司，有限责任合伙企业 | 2020-10-23 | — | — | CN | claimed |
| CN-111494291-A | Blue light resisting and aging delaying skin care cosmetic and preparation method thereof | 珠海越美科技有限公司 | 2020-08-07 | — | — | CN | claimed |
| CN-111095609-A | Laser ablation for manufacturing battery cells | 戴森技术有限公司 | 2020-05-01 | — | — | CN | claimed |
| EP-3168285-B1 | GEL COMPRISING A LAMELLAR PHASE COMPOSITION | PROCTER & GAMBLE (US) | 2019-08-14 | — | — | EP | claimed |
| EP-3292191-B1 | ALKALINE DISHWASH COMPOSITION | UNILEVER NV (NL) | 2019-06-05 | — | — | EP | claimed |
| US-10005992-B2 | Gel comprising a lamellar phase composition comprising a glycerol and dipropyleneglycol solvent | THE PROCTER & GAMBLE COMPANY (US) | 2018-06-26 | — | — | US | claimed |
| EP-3292191-A1 | ALKALINE DISHWASH COMPOSITION | Unilever N.V. (NL) | 2018-03-14 | — | — | EP | claimed |
| US-20170137759-A1 | Gel Comprising a Lamellar Phase Composition | THE PROCTER & GAMBLE COMPANY | 2017-05-18 | — | — | US | claimed |
| EP-3168285-A1 | GEL COMPRISING A LAMELLAR PHASE COMPOSITION | The Procter and Gamble Company (US) | 2017-05-17 | — | — | EP | claimed |
| WO-2016177563-A1 | ALKALINE DISHWASH COMPOSITION | UNILEVER N.V. (NL) | 2016-11-10 | — | — | WO | claimed |
| US-20240018085-A1 | SITE-SPECIFIC ISOTOPIC LABELING OF 1,4-DIENE SYSTEMS | BIOJIVA LLC | 2024-01-18 | — | — | US | disclosed |
| US-20230404960-A1 | DISORDERS IMPLICATING PUFA OXIDATION | BIOJIVA LLC (US) | 2023-12-21 | — | — | US | disclosed |
| US-20220378734-A1 | NEURODEGENERATIVE DISORDERS AND MUSCLE DISEASES IMPLICATING PUFAS | RTMFP ENTERPRISES INC. | 2022-12-01 | — | — | US | disclosed |
| US-20220133668-A1 | ISOTOPICALLY MODIFIED COMPONENTS AND THERAPEUTIC USES THEREOF | BIOJIVA LLC | 2022-05-05 | — | — | US | disclosed |
| EP-3950649-A1 | SITE-SPECIFIC ISOTOPIC LABELING OF 1, 4-DIENE SYSTEMS | Retrotope, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| US-20040096484-A1 | Antioxidant-containing wipes and absorbent products for improving skin health | KIMBERLY-CLARK WORLDWIDE, INC. | 2004-05-20 | — | — | US | disclosed |
| US-20040024233-A1 | Fatty acid esters composition of a polyglycerine, a process for the preparation thereof, a process for the preparation of a highly-purified fatty acid esters composition of a polyglycerine, a highly-purified fatty acid esters composition of a polyglycerine, an additive for food-stuffs, a resin composition, and a composition for cosmetics or detergents | ENDO TOSHIO (JP) | 2004-02-05 | — | — | US | disclosed |
| CN-1210549-A | Preparation of double metal cyanide-catalyzed polyols by continuous addition of starter | ARCO CHEM TECH (US) | 1999-03-10 | — | — | CN | disclosed |
| CN-1014955-B | Cosmetic preparation | KAO CORP (JP) | 1991-12-04 | — | — | CN | disclosed |
| CN-88100344-A | Cosmetics | — | 1988-08-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018085-A1 | SITE-SPECIFIC ISOTOPIC LABELING OF 1,4-DIENE SYSTEMS | FADS1, FASN, FADS2 | LMNA 2040/4885ALDH1A1 832/4885THRB 1291/4885 |
| US-20220378734-A1 | NEURODEGENERATIVE DISORDERS AND MUSCLE DISEASES IMPLICATING PUFAS | CPT1B, PSEN2, NLN | LMNA 637/4885ALDH1A1 2738/4885THRB 3562/4885 |
| US-20230404960-A1 | DISORDERS IMPLICATING PUFA OXIDATION | GPX4, CPT1A, FABP1 | LMNA 806/4885ALDH1A1 298/4885THRB 1462/4885 |
| US-20040024233-A1 | Fatty acid esters composition of a polyglycerine, a process for the preparation thereof, a process for the preparation of a highly-purified fatty acid esters composition of a polyglycerine, a highly-purified fatty acid esters composition of a polyglycerine, an additive for food-stuffs, a resin composition, and a composition for cosmetics or detergents | FASN, DGAT2, SCD5 | LMNA 2832/4885ALDH1A1 731/4885THRB 1980/4885 |
| US-20220133668-A1 | ISOTOPICALLY MODIFIED COMPONENTS AND THERAPEUTIC USES THEREOF | ACADM, CPT1A, ALDH2 | LMNA 1125/4885ALDH1A1 54/4885THRB 1921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.